The investment will focus on the following areas:

• Transformational capabilities in cell engineering and gene editing
• Value-added starting materials, including cell sourcing
• Process science and scale-up tools and services
• Production technologies
• Source-to-patient delivery

Kiniciti intends to invest in cell and gene therapy opportunities in a range of sizes and locations. Its strategy rests upon a flexible investment model to ensure companies supporting cell and gene customers have access to the resources needed to rapidly advance therapies.

The Kiniciti leadership team includes CEO Geoffrey Glass and chief strategy officer Jason Conner. Glass has more than 25 years of experience leading life sciences services and therapeutic companies. Conner has held senior strategy, corporate development, and leadership roles in multiple life sciences and services firms.

Adverum publishes long-term safety data of gene therapy candidate
Adverum Biotechnologies has published preclinical data on its intravitreal gene therapy candidate ADVM-022 in Translational Vision Science & Technology.

Researchers develop new gene therapy vector for blood disorders
Researchers at Children's Hospital of Philadelphia have developed a new gene therapy vector for blood disorders that is safer and more effective than...

Thermo Fisher introduces cell therapy workflow media
Thermo Fisher Scientific has launched a new medium of the first human T lymphocytes (T cells) specifically designed for allogeneic cell therapy workflows.

Dual-antigen CAR T system could be effective at treating solid tumors in children
A new chimeric antigen receptor (CAR) T-cell system that targets two tumor antigens may be effective at treating difficult solid tumors in children in...

Kuur provides positive interim clinical data for CAR-NKT cell therapy programs
Kuur Therapeutics has released results from phase I clinical trials evaluating its off-the-shelf chimeric antigen receptor natural killer T (CAR-NKT)-cell...